Categories
Tag: CXCR4
Unravelling cell type-specific responses to Parkinson’s Disease at single cell resolution | Molecular Neurodegeneration
Single nucleus RNA-seq reveals cell type heterogeneity in human SNpc We sampled SNpc from post-mortem human brains of 15 sporadic Parkinson’s disease (PD) patients and 14 Control individuals (see Supplementary Table 1 for full pathology reports). Using a 10X Genomics Chromium platform, we performed single nucleus RNA-seq (snRNA-seq) on more than…
dashed PDB file/OXT residues
I think it is clear what is going on once you do a few things. Download and read the header of the PDB file for 3odu: HEADER SIGNALING PROTEIN, HYDROLASE 11-AUG-10 3ODU TITLE THE 2.5 A STRUCTURE OF THE CXCR4 CHEMOKINE RECEPTOR IN COMPLEX WITH TITLE 2 SMALL MOLECULE ANTAGONIST…
Harnessing Nanomedicine to Combat Hepatic Fibrosis
Understanding nanomedicinesNanomedicine in hepatic fibrosis diagnosisNanomedicine in hepatic fibrosis treatmentNanomedicine in drug delivery Nanomedicine in targeted drug delivery Future perspectivesReferencesFurther reading Hepatic fibrosis is an abnormal wound-healing response triggered by chronic liver diseases, including non-alcoholic fatty liver disease, viral or alcoholic hepatitis, and Wilson’s disease. The response is characterized by…
Comprehensive Review of Small Interfering RNAs (siRNAs)
Introduction Cancer, also called malignancy, is a group of diseases caused by the rapid multiplication and spread of malignant cells.1,2 According to statistics from the National Cancer Center, more than 100 types of cancer have been identified.3 The ability of malignant tumor cells to metastasize via the blood-lymphatic system and…
X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023
X4 Pharmaceuticals Initial data continue to support advancement of mavorixafor into pivotal, global Phase 3 trial in certain chronic neutropenic disorders; company on track to initiate in 1H 2024 X4 expects to present additional CN Phase 2 clinical trial data in 1H 2024 BOSTON, Dec. 09, 2023 (GLOBE NEWSWIRE) —…
Noncoding mutations cause super-enhancer retargeting resulting in protein synthesis dysregulation during B cell lymphoma progression
B cells undergo a series of programmed genomic alterations that enable the immunoglobulin light and heavy chain loci to generate high-affinity antibodies against invading pathogens. First, B cells undergo variability, diversity and joining (VDJ) recombination in the bone marrow with subsequent somatic hypermutation (SHM) and class switch recombination (CSR) occurring…
Dissemination feature based on PET/CT is a risk factor for diffuse large B cell lymphoma patients outcome | BMC Cancer
Sehn LH, Salles G. Diffuse large B-Cell lymphoma. N Engl J Med. 2021;384(9):842–58. Article CAS PubMed PubMed Central Google Scholar Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185…
Primate-specific ZNF808 is essential for pancreatic development in humans
Subjects The study was conducted in accordance with the Declaration of Helsinki and all subjects or their parents/guardian gave informed written consent for genetic testing. DNA testing and storage in the Beta Cell Research Bank was approved by the Wales Research Ethics Committee 5 Bangor (REC 17/WA/0327, IRAS project ID…
X4 Pharmaceuticals outlines plans for drug candidate mavorixafor, eyes Q2 2024 launch By Investing.com
© Reuters. X4 Pharmaceuticals (NASDAQ:), during its third-quarter financial and operating results conference call, revealed that the FDA has accepted its New Drug Application (NDA) for mavorixafor, a leading drug candidate for the treatment of WHIM syndrome. The company is preparing for a potential US launch in Q2 2024, subject…
IJMS | Free Full-Text | CRISPR/Cas9 Landscape: Current State and Future Perspectives
1. Introduction Genome editing has taken a leading position among genome modification technologies in a short time and is now widely used in gene therapy. To date, there are three main systems for genome editing: zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and CRISPR/Cas nucleases. Genome editing has…
Preparation and in vitro Activity of Anti-EpCAM Immunotoxin
Preparation and in vitro Activity of Anti-EpCAM Immunotoxin LIU Yu-ping1,DENG Chang-ping2,MA Xing-yuan2,LIU Qiu-li1,BAO Wen1,ZHENG Wen-yun1,**() 1 Shanghai Key Laboratory…
CRISPR-Cas9 gene editing in liver disease
Introduction to CRISPR-Cas9 Gene EditingLiver disease: the need for innovative treatmentsCRISPR-Cas9 applications in liver diseasePrecision medicine and personalized treatmentFuture prospects and research directionsrefer to further reading CRISPR-Cas9 gene editing has great potential in the field of precision medicine for liver diseases. This innovative technology allows researchers to precisely modify genes…
A diphtheria toxin-based nanoparticle achieves specific cytotoxic effect on CXCR4(+) lymphoma cells without toxicity in immunocompromised and immunocompetent mice
Falgàs A; Garcia-León A; Núñez Y; Serna N; Sánchez-Garcia L; Unzueta U; Voltà-Durán E; Aragó M; Álamo P; Alba-Castellón L; Sierra J; Gallardo A; Villaverde A; Vázquez E; Mangues R; Casanova I. BIOMED PHARMACOTHER High rates of relapsed and refractory diffuse large B-cell lymphoma (DLBCL) patients and life-threatening side effects…
A spatial sequencing atlas of age-induced changes in the lung during influenza infection
Single-cell RNA sequencing reveals cellular heterogeneity among young and aged lungs post-influenza infection In order to investigate age-induced alterations in the host response to influenza A virus (IAV) infection, we infected groups of three young (16–18-week-old) and three aged (80–82-week-old) female C57Bl/6 mice intranasally with 50 PFU of the PR8…
The potential use of bacteria and bacterial derivatives as drug delivery systems for viral infection | Virology Journal
Novel approaches to treating viral illnesses must be developed. Drug delivery methods based on nanomaterials are attractive options in the search for therapeutic advantages because of their distinctive properties. Researchers should also examine how the most prevalent viruses, such as the flu, HIV, SARS-CoV-2, monkeypox, and HPVs, are being treated…
Innovative strategies of reprograming immune system cells
Introduction Cancer is well characterized by genomic instability resulting in structural alterations that build up with tumor progression.1,2 A subpopulation of undifferentiated cancer cells, known as cancer stem cells (CSCs) are found within the tumor bulk. These cells are responsible for cancer initiation, recurrence and show therapeutic resistance and these…
Drug delivery systems for CRISPR-based genome editors
Li, Y., Glass, Z., Huang, M., Chen, Z. Y. & Xu, Q. Ex vivo cell-based CRISPR/Cas9 genome editing for therapeutic applications. Biomaterials 234, 119711 (2020). Article CAS PubMed PubMed Central Google Scholar Dong, W. & Kantor, B. Lentiviral vectors for delivery of gene-editing systems based on CRISPR/Cas: current state and…
Calcium electroporation of esophageal cancer induces gene expression changes: a sub-study of a phase I clinical trial
Ágoston D, Baltás E, Ócsai H, Rátka S, Lázár PG, Korom I et al (2020) Evaluation of calcium electroporation for the treatment of cutaneous metastases: a double blinded randomised controlled phase II trial. Cancers. doi.org/10.3390/cancers12010179 Article PubMed PubMed Central Google Scholar Alrumaihi F (2022) The multi-functional roles of CCR7 in…
X4 Pharmaceuticals Announces Submission of New Drug Application (NDA) to U.S. FDA for Mavorixafor in WHIM Syndrome | Small Molecules
X4 Pharmaceuticals Announces Submission of New Drug Application (NDA) to U.S. FDA for Mavorixafor in WHIM Syndrome Details Category: Small Molecules Published on Tuesday, 05 September 2023 18:24 Hits: 139 Submission supported by positive results from global, pivotal 4WHIM Phase 3 clinical trial BOSTON, MA, USA I September 05,…
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
X4 Pharmaceuticals BOSTON, Sept. 01, 2023 (GLOBE NEWSWIRE) — X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with rare diseases of the immune system, today announced that, effective on August 31, 2023, the company issued inducement awards to new employees…
Dynamic thresholding and tissue dissociation optimization for CITE-seq identifies differential surface protein abundance in metastatic melanoma
Workflow overview CITE-seq and cell hashing were performed on liquid and solid tissue biopsies (Fig. 1a, b). Experimentally, cells from 17 samples (Supplementary Data 2) were hashed and stained with a panel of 97 antibodies (Supplementary Data 2) covering key as well as exploratory immuno-oncology markers resulting in 57,261 cells after preprocessing and…
Potent and uniform fetal hemoglobin induction via base editing
Piel, F. B., Steinberg, M. H. & Rees, D. C. Sickle cell disease. N. Engl. J. Med. 376, 1561–1573 (2017). Article CAS PubMed Google Scholar Taher, A. T., Musallam, K. M. & Cappellini, M. D. Beta-thalassemias. N. Engl. J. Med. 384, 727–743 (2021). Article PubMed Google Scholar Doerfler, P. A….
The quahog makes a tasty chowder, but it can also edit your genome
It’s been a really good week for bivalves. Why, just a week ago in the journal Science we found out that the shell hinge from the freshwater cockscomb mussel can be opened and closed 1,500,000 times in succession without suffering any fatigue damage (!), and we also learned the structural secret…
Recombinant Human CD25 – IL-2RA (CHO)
Product Type SelectAntibody (536)Biologically Active (52)Capture Antibody (26)Cytokine (6)Detection Antibody (26)Dual ELISpot Set (9)Dual Fluorospot Set (9)ELISA Kit (111)ELISA Set (36)ELISpot Kit (22)ELISpot Pairs (20)ELISpot Set (20)Isotype Control (17)Recombinant Antibody (12)Recombinant Protein (19)SARS-CoV-2 (11)SARSCoV2 (8) Analyte SelectADAM-10 (1)Angiopoietin-2 (3)BCMA (2)BIOTIN (1)c-Myc (1)CD10 (4)CD102 (1)CD102 / ICAM-2 (4)CD105 (5)CD106 (2)CD106 /…
Diagnosis in Ectopic Pregnancy | IJGM
Introduction As the leading cause of maternal mortality in early pregnancy, ectopic pregnancy (EP) is responsible for 4–10% of all pregnancy-related deaths,1 but drugs can only be used to treat early EP. However, significant differences in the effects on fertility between surgical treatment and medical treatment have been reported in…
Establishment of risk model, analysis of immunoinfiltration
Introduction Atrial fibrillation (AF) is a tachyarrhythmia whose incidence and prevalence are steadily increasing with better chronic disease management in the aging global population. As of 2020, 37.5 million patients worldwide were affected by AF, accounting for 0.51% of the global population.1 As a common arrhythmia, AF greatly increases the…
Bioinformatics and system biology approach to identify potential common pathogenesis for COVID-19 infection and osteoarthritis
Hunter, D. J. & Bierma-Zeinstra, S. Osteoarthritis. Lancet 393, 1745–1759 (2019). Article CAS PubMed Google Scholar Puig-Junoy, J. & Ruiz Zamora, A. Socio-economic costs of osteoarthritis: A systematic review of cost-of-illness studies. Semin. Arthritis Rheum. 44, 531–541 (2015). Article PubMed Google Scholar Hunter, D. J., March, L. & Chew, M….
Lipid nanoparticles-based therapy in liver metastasis
Key Points Liver metastasis, which is highly prevalent in advanced malignancies, was associated with poor prognosis. Contemporary therapies in liver metastasis were associated with the lack of metastatic-targeting ability, significant systemic toxicities and incapability of tumor microenvironment (TME) modulations. Lipid nanoparticles (LNP)-based strategies would overcome the deficiencies of conventional approaches…
Human Immunodeficiency Virus Related Non-Hodgkin’s Lymphoma
Introduction Human immunodeficiency virus (HIV) infection is associated with an increased risk of hematological malignancy. Lymphoid neoplasms, particularly non-Hodgkin lymphoma, are the main hematologic malignancies that occur more frequently in connection with HIV infection non-Hodgkin lymphoma (NHL).1 Lymphomas are neoplastic lesions of the lymphoid system. According to World Health Organization…
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
On Track for September PDUFA Target Action Date on NDA for Motixafortide in Stem Cell Mobilization (SCM) for Autologous Transplantation in Multiple Myeloma (MM) Rapidly Advancing U.S. Commercial Activities in Support of Potential September Launch Announced Publication in Nature Medicine of GENESIS Phase 3 Clinical Trial Data Evaluating Motixafortide and…
Screening and verification of key ubiquitination genes
Introduction Liver cancer is the third most common cause of cancer death globally with hepatocellular carcinoma (HCC) accounting for the majority of liver cancer.1,2 Early HCC (stage I/II) treatment mainly includes radical surgical resection, radiofrequency ablation and liver transplantation.3,4 However, there is a lack of typical clinical symptoms with early-stage…
X4 Pharmaceuticals Announces Positive Phase 3 Results
~60% reduction in annualized infection rate seen in the mavorixafor arm vs. placebo (p<0.01) >75% reduction in the percentage of individuals experiencing severe infections (Grade 3 or higher) in the mavorixafor group vs. placebo group >70% reduction in mean total days with infections (2 weeks on mavorixafor treatment vs. 7…
Influence of corticosteroid treatment on CXCR4 expression in DLBCL
Background: CXCR4-targeted radioligand therapy (RLT) with [177Lu]Lu/[90Y]Y-PentixaTher has recently evolved as a promising therapeutic option for patients with advanced hematological cancers. Given their advanced disease stage, most patients scheduled for PentixaTher RLT require concomitant or bridging chemotherapy to prevent intermittent tumor progression. These (mostly combination) therapies may cause significant downregulation…
X4 Pharmaceuticals Reports First-Quarter 2023 Financial Results and Provides Corporate Update
X4 Pharmaceuticals Reports First-Quarter 2023 Financial Results and Provides Corporate Update Company to host webinar event on May 16 th presenting new clinical data from the 4WHIM Phase 3 trial; oral presentation to follow on May 21 st at the 2023 Clinical Immunology Society (CIS) Annual Meeting U.S. NDA submission…
X4 Pharmaceuticals Reports First-Quarter 2023 Financial
Company to host webinar event on May 16th presenting new clinical data from the4WHIM Phase 3 trial; oral presentation to follow on May 21st at the 2023Clinical Immunology Society (CIS) Annual Meeting U.S. NDA submission of mavorixafor for WHIM syndrome on track for early 2H 2023 Presentation of data from…
Uproleselan Combinations Contribute to Robust Investigational Profile in AML
Michael Andreeff, MD, PhD The E-selectin inhibitor uproleselan (GMI-1271) has shown preliminary efficacy in patients with acute myeloid leukemia (AML), and E-selectin could represent one of several novel targets for treatment of this patient population, according to Michael Andreeff, MD, PhD. Previously, a phase 1/2 trial (NCT02306291) investigating uproleselan plus…
Peptide-mediated delivery of CRISPR enzymes for the efficient editing of primary human lymphocytes
Weber, E. W., Maus, M. V. & Mackall, C. L. The emerging landscape of immune cell therapies. Cell 181, 46–62 (2020). CAS PubMed PubMed Central Google Scholar Eyquem, J. et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature 543, 113–117 (2017). CAS PubMed PubMed…
Immune cell dynamics deconvoluted by single-cell RNA sequencing in normothermic machine perfusion of the liver
Study cohort and performance during NMP An overview of the overall study population is presented in Table 1 (individual data are given in Supplementary Table 1). Detailed information on study livers and analysis is provided as workflow scheme in Fig. 1. The decision to apply NMP was based on one or a combination…
BioLineRx Announces Publication in Nature Medicine of its GENESIS Phase 3 Clinical Trial Data Evaluating Motixafortide and G-CSF in Stem Cell Mobilization for Autologous Transplantation in Multiple Myeloma – BioLine Rx (NASDAQ:BLRX)
– GENESIS trial achieved statistical significance (p<0.0001) across all primary and secondary endpoints – – Nature Medicine publication describes how GENESIS trial included patients representative of current multiple myeloma population undergoing autologous HSCT, including older patients and those who received lenalidomide-containing induction therapies – factors associated with impaired HSPC mobilization…
Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial
Patient demographics were comparable across study cohorts From 22 January 2018 to 30 October 2020, a total of 122 patients from 18 sites in five countries were enrolled and randomized 2:1 to receive either motixafortide + G-CSF (80 patients) or placebo + G-CSF (42 patients) for HSPC mobilization (Fig. 1 and Extended Data Fig. 1a). Demographics between the two treatment…
Cancer: Enhancing stem-cell mobilization for transplantation in multiple myeloma | Nature Medicine
A new compound, motixafortide, can safely mobilize an optimal number of stem cells for collection and transplantation in over 90% of 80 patients with multiple myeloma (a cancer of the bone marrow) with 1 injection, reports a phase 3 clinical trial published in Nature Medicine. This approach could improve treatment…
Modulation of tau tubulin kinases (TTBK1 and TTBK2) impacts ciliogenesis
Design and synthesis of indolyl pyrimidinamine inhibitors of TTBK1/2 Our lead (AMG28, Fig. 1A) emerged from examination of the off-target activity of a published Amgen NF-κB inducing kinase (NIK) inhibitor27. The potency of AMG28 was reported in the MRC Kinase Profiling Inhibitor Database as 8% activity remaining for TTBK1 and 12%…
HSPCs and off-target effects of CRISPR-Cas9
Sponsored Content by MaxCyte, Inc.Apr 13 2023Reviewed by Maria Osipova Efficient and reliable delivery of DNA, mRNA, and Ribonucleoprotein (RNP)-based reagents into primary and stem cells is imperative for precision genome engineering. For clinical gene editing, a transfection platform that does not compromise genome stability and cell viability, is required. The…
X4 Pharmaceuticals Announces Late-Breaking Abstract of WHIM
X4 to host virtual investor event on Tuesday, May 16 CIS oral presentation to take place on Sunday, May 21 BOSTON, April 12, 2023 (GLOBE NEWSWIRE) — X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of…
X4 Pharmaceuticals Announces Late-Breaking Abstract of WHIM Phase 3 Clinical Data Accepted for Oral Presentation at the 2023 Annual Meeting of the Clinical Immunology Society (CIS) – X4 Pharmaceuticals (NASDAQ:XFOR)
X4 to host virtual investor event on Tuesday, May 16 CIS oral presentation to take place on Sunday, May 21 BOSTON, April 12, 2023 (GLOBE NEWSWIRE) — X4 Pharmaceuticals, Inc. XFOR, a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of the…
Optimization of Cas9 activity through the addition of cytosine extensions to single-guide RNAs
Cell culture We cultured mESCs in t2iL medium containing Dulbecco’s modified eagle medium (DMEM, Nacalai Tesque), 2 mM Glutamax (Nacalai Tesque), 1× non-essential amino acids (Nacalai Tesque), 1 mM sodium pyruvate (Nacalai Tesque), 100 U ml−1 penicillin, 100 μg ml−1 streptomycin (P/S) (Nacalai Tesque), 0.1 mM 2-mercaptoethanol (Sigma) and 15% fetal bovine serum (FBS) (Gibco), supplemented with…
Inactivation of interleukin-30 in colon cancer stem cells via CRISPR/Cas9 genome editing inhibits their oncogenicity and improves host survival
Introduction Colorectal cancer (CRC) is a leading cause of cancer-related death1 and its mortality rate is expected to rise worldwide, due to population growth and aging, thus entailing a global public health challenge. CRC mortality is mainly due to therapy resistance and metastasis, which are driven by a small population…
Alzheimer’s Gene MS4A4A Governs the State of Microglia
03 Mar 2023 Of the dozens of loci genome-wide association studies have linked to Alzheimer’s, most are mysterious to scientists. How do they contribute to disease? Much work focuses on changes in expression of individual genes, but as reported in a preprint posted to medRxiv on February 8, scientists led…
CRISPR screens identify novel regulators of cFLIP dependency and ligand-independent, TRAIL-R1-mediated cell death
Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med. 1995;332:1186–91. Article CAS PubMed Google Scholar Nador RG, Cesarman E, Chadburn A, Dawson DB, Ansari MQ, Sald J, et al. Primary effusion lymphoma: a distinct clinicopathologic entity…
Beyond Biotech podcast 34
This week, our guests are Katrina Rice, chief delivery officer, biometrics services at eClinical Solutions; Pina Cardarelli, president and CSO of GPCR Therapeutics; and Larry A Couture, CEO of Orbsen Therapeutics. GPCR Therapeutics launches multiple myeloma trial GPCR Therapeutics, Inc., a drug discovery company targeting G Protein Coupled Receptors (GPCR)…
Antineoplastic effect of therapeutic nanoparticles targeted to CXCR4+ diffuse large b-cell lymphoma cells
Nowadays, novel therapeutic strategies are urgently needed to reduce relapse rates after R-CHOP treatment and to enhance the survival of diffuse large B-cell lymphoma (DLBCL) patients. Selective delivery of antineoplastic agents to cancer cells, using actively-targeted nanoparticles, is a novel approach that promises to revolutionize therapy by dramatically increasing the…
SLC7A11 is a prognostic biomarker in UCEC
Introduction Endometrial cancer (EC) is one of the most frequently diagnosed types of gynecological cancers, second only to cervical cancer in incidence.1 More than 50,000 women die from EC worldwide each year.2 Despite the development of diagnostic techniques and treatment means, the prognosis of advanced EC remains unsatisfactory.3,4 The therapeutic…
Generation of mesenchymal stromal cells from urine-derived iPSCs of pediatric brain tumor patients
Introduction In 2006, there was a breakthrough in the field of regenerative medicine, when Takahashi and Yamanaka developed the technology to transform any somatic cell into a pluripotent stem cell. These reprogrammed cells, called induced Pluripotent Stem Cells (iPSCs), can be generated by ectopic expression of four transcription factors (i.e….
Download “Epigenetic Memory” Phenomenon in Induced Pluripotent Stem Cells. PDF
reVIeWS “Epigenetic Memory” Phenomenon in Induced Pluripotent Stem Cells E.A. Vaskova1,2,3, A.E. Stekleneva1,2,3, S.P. Medvedev1,2,3, S.M. Zakian1,2,3,* 1Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences, prosp. Akad. Lavrentyeva, 10, Novosibirsk, Russia, 630090 2Meshalkin State Research Institute of Circulation Pathology, Rechkunovskaya Str., 15, Novosibirsk, Russia, 630055 3Institute of…
dot-lot code issue
pdf(file=”celltype_markergene_dotplot.pdf”,width=20) DotPlot(data, features =c(“DCN”, “COL1A2”, “CFD”, “KLRB1”, “CD7”, “GZMK”, “MT1G”, “MT1H”, “MT1F”, “HSPA1A”, “HSPA6”, “DNAJB1”, “CCL5”, “CD3E”, “CXCR4”, “IFI27”, “TM4SF1”, “CLDN5”, “HLA-DRA”, “HLA-DPB1”, “HLA-DQB1”, “S100A9”, “S100A8”, “LST1”, “GNLY”, “GZMB”, “FGFBP2”, “S100A2”, “SFN”, “KRT14”, “CCL4”, “CCL3”, “NKG7”, “ALDOB”, “PCK1”, “MT1G”, “S100A8”, “S100A9”, “FCGR3B”, “PRSS1”, “CLPS”, “PNLIP”, “SFTPC”, “CXCL2”, “SFTPA1”, “HSPA6”, “HSPA1A”,…
Evasion of cGAS and TRIM5 defines pandemic HIV
Cells and reagents HEK293T and U87 cells were maintained in DMEM medium (Gibco) supplemented with 10% fetal bovine serum (FBS, Labtech) and 100 U ml−1 penicillin plus 100 μg ml−1 streptomycin (Pen/Strep; Gibco). THP-1-IFIT1 cells that had been modified to express Gaussia luciferase under the control of the IFIT1 promoter were described previously62. THP-1…
BTG2 gene predicts poor outcome in PT-DLBCL
Introduction Primary testicular diffuse large B-cell lymphoma (PT-DLBCL) is a rare and aggressive form of mature B-cell lymphoma.1–3 PT-DLBCL was the most common type of testicular tumor in men aged over 60 and characterized by painless uni- or bilateral testicular masses with infrequent constitutional symptoms.4–6 PT-DLBCL shows significant extranodal tropism,…
Identification of Hub Genes Associated with COPD Through Integrated Bi
Introduction Chronic obstructive pulmonary disease (COPD) will become the third leading cause of death worldwide.1,2 The incidence of COPD worldwide is 13.1%3 and is 13.7% in the Chinese population over 40 years of age.4 Emphysema is one of the most common phenotypes.1 Over the past few decades, we have conducted…
Identification of differentially expressed genes in AF
Defeng Pan,1,* Yufei Zhou,2,* Shengjue Xiao,1,* Yue Hu,3,* Chunyan Huan,1 Qi Wu,1 Xiaotong Wang,1 Qinyuan Pan,1 Jie Liu,1 Hong Zhu1 1Department of Cardiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221004, People’s Republic of China; 2Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital and Institutes of…
Crosstalk between Venous Thromboembolism and Periodontal Diseases: A Bioinformatics Analysis
This article was originally published here Dis Markers. 2021 Dec 10;2021:1776567. doi: 10.1155/2021/1776567. eCollection 2021. ABSTRACT BACKGROUND: This current study applied bioinformatics analysis to reveal the crosstalk between venous thromboembolism (VTE) and periodontitis, as well as the potential role of immune-related genes in this context. METHODS: Expression data were downloaded…
r – Error in colSums(mat) : ‘x’ must be numeric GOchord plot
I was trying to plot the gene chord diagram, but I got an error” Error in colSums(mat) : ‘x’ must be numeric”. I prepared the file myself, I submitted the target genes on Metascape, all these genes were enriched and picked from 6 signal pathways clusters. And then I downloaded…
Establishment of sunitinib-resistant CDX model of ccRCC
Introduction Renal cell carcinoma (RCC) accounts for approximately 2–3% of all malignant tumors, and its prevalence is rising. Metastatic RCC accounts for 25–30% of all RCC cases, and has an exceedingly poor prognosis.1 In 2020, among approximately 430,000 newly discovered cases of RCC, 179,000 died.2 Clear cell renal cell carcinoma…
Gene expression profiling of contralateral dorsal root gangl
Introduction Mirror-image pain (MIP) is a mysterious pain phenomenon which is accompanied with many clinical pain conditions.1 MIP develops from the healthy body region which is contralateral to the actual injured site.1–3 MIP is typically characterized by increased mechanical hypersensitivity on the uninjured mirror-image body side.4 It can be triggered…
CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model
This article was originally published here Cancer Gene Ther. 2021 Sep 1. doi: 10.1038/s41417-021-00365-x. Online ahead of print. ABSTRACT The highly restricted expression of B-cell maturation antigen (BCMA) on plasma cells makes it an ideal target for chimeric antigen receptor (CAR) immune cell therapy against multiple myeloma (MM), a bone…